

# Mary M Taj

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5797372/publications.pdf>

Version: 2024-02-01

17  
papers

226  
citations

1163117

8  
h-index

1058476

14  
g-index

17  
all docs

17  
docs citations

17  
times ranked

316  
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1882-1888.	1.3	43
2	Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children. <i>British Journal of Haematology</i> , 2008, 140, 191-196.	2.5	34
3	Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: a United Kingdom Children's Cancer Study Group (UKCCSG) retrospective review. <i>Leukemia and Lymphoma</i> , 2006, 47, 2584-2589.	1.3	33
4	Rare non-Hodgkin lymphoma of childhood and adolescence: A consensus diagnostic and therapeutic approach to pediatric-type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T-cell lymphoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28416.	1.5	32
5	Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations. <i>Cancers</i> , 2021, 13, 2075.	3.7	23
6	Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma. <i>Leukemia</i> , 2022, 36, 781-789.	7.2	20
7	Primary post-transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome in 25 paediatric patients. <i>British Journal of Haematology</i> , 2021, 193, 1178-1184.	2.5	11
8	Preliminary experience on the use of PET/CT in the management of pediatric post-transplant lymphoproliferative disorder. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26685.	1.5	9
9	Long-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004. <i>Leukemia and Lymphoma</i> , 2012, 53, 842-848.	1.3	7
10	High-dose etoposide and cyclophosphamide in adults and children with primary refractory and multiply relapsed acute leukaemias: The Royal Marsden experience. <i>Leukemia Research</i> , 2019, 85, 106217.	0.8	5
11	Long-term risk of portal hypertension and related complications in children treated with 6-thioguanine for acute lymphoblastic leukemia: A single-center experience. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26495.	1.5	4
12	Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1010-1012.	1.3	2
13	Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols. <i>Leukemia</i> , 2021, , .	7.2	2
14	Pediatric EBV-negative monomorphic post-solid organ transplant lymphoproliferative disorders [EBV(-)M-PTLD]: Characteristics, treatment, and outcome from 11 pediatric academic centers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10012-10012.	1.6	1
15	Reply to: Role of PET-CT in management of post-transplant lymphoproliferative disorder. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26807.	1.5	0
16	Childhood post-transplant lymphoproliferative disorder. <i>Paediatrics and Child Health (United Kingdom)</i> 10.1016/j.pedch.2014.05.014	0.4	0
17	Risk stratification to guide long-term follow up of teenage and young adult survivors of childhood cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10069-10069.	1.6	0